UNSPSC 51182075: Testosterone propionate

This classification denotes a therapeutic testosterone with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WI93Z9138A, chemically known as testosterone, propionate but more generally known as testosterone propionate, which bears US NIH Compound Identifier 5995. European Medicines Agency schedules Testosterone propionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04743MIG.

Most nations, for tariff and trade purposes, schedule testosterone propionate under HS 29372900 and SITC 54153. As of Q4 2014, TESTOSTERONE PROPIONATE remains US FDA's Preferred Term for this commodity. Testosterone propionate bears US NLM identifiers UMLS ID C0039607 and NCI Concept Code C863. SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C.

UNSPSC 51182075 Testosterone propionate is a Commodity code representing a single pharmaceutical product line that state and local government health systems procure through cooperative purchasing vehicles and multistate pharmaceutical contracts. The code encompasses the supply and distribution of this controlled steroid medication to public healthcare facilities, clinics, and correctional health systems, typically acquired as part of broader generic pharmaceutical and over-the-counter product frameworks negotiated with authorized drug wholesalers.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (solicitation S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026. MMCAP's RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and mandates certification of current Good Manufacturing Practices (cGMP) compliance, Drug Supply Chain Security Act (DSCSA) compliance, and maintenance of contractual relationships with at least two of the three authorized wholesalers. Evaluation weights price competitiveness at 75 percent, with smaller allocations for fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. The contract term is two years for new vendors with optional extensions at MMCAP's discretion, with awarded vendors effective July 1, 2026. Vendors must maintain commercial general liability insurance of $5 million per occurrence and submit detailed product information including National Drug Codes (NDC), SKUs, and UPCs through the ePro procurement system using designated Excel spreadsheet formats.